secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2025-07-01T23:59:59+00:00
Accession:  0001213900-25-060366
Event type: regulatory
Sentiment:  positive
Materiality: 0.45
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics receives Australian patent acceptance for stenoparib DRP companion diagnostic
--------------------------------------------------------------------------------

- IP Australia accepted patent application covering 40 claims for DRP companion diagnostic specific to stenoparib.
- Patent to be advertised June 26, 2025; three-month opposition period; grant expected within 20 working days if unopposed.
- Company holds 18 granted drug-specific DRP patents, including 8 in US; European patent for stenoparib DRP previously secured.
- Applications pending in US, Canada, Japan, China, and India.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390025060366/0001213900-25-060366-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390025060366/ea0247668-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-060366

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer